Table 8 includes a list of the measures with infor- mation on the attribution and a brief rationale. Perfor- mance measures are typically outcome measures that target meaningful gaps in the quality of care, are based on Class 1 clinical practice guideline recommendations, and are appropriately designed for use in accountability in programs that rely on public reporting and pay-for- value initiatives promoted by organizations such as CMS, commercial payers, the NCQA, and the NQF. The writ- ing committee believes that it is important to confirm its Table 6. Associated Clinical Practice Guidelines and Other Clinical Guidance Documents Clinical Practice Guidelines Performance Measures and Scientific Statements 2 NQF Measure 0018 Controlling High Blood Pressure (NCQA)22 3 ACC/AHA Performance Measures Methodology1 ACC indicates American College of Cardiology; AHA, American Heart Association; NCQA, National Committee for Quality Assurance; NQF, National Quality Forum; and USPSTF, US Preventive Services Task Force. 9 full support of the performance measure for BP control in current widespread use by CMS and NCQA for HBP (ie, the proportion of stage 2 patients with HBP with control below the Joint National Committee5 traditional target of 140/90 mmHg). In addition, the writing committee unanimously feels it important to include new harmoniz- ing measures for stage 1 HBP and a composite measure (ie, for ACC/AHA stage 2 and ACC/AHA stage 1 com- bined) that emphasize the importance of controlling HBP below the new ACC/AHA target of 130/80 mmHg, as recommended by the 2017 Hypertension Clinical Practice Because of the importance of the promo- tion of intensive nonpharmacological healthy lifestyle modifications and home BP monitoring for patients with stage 2 HBP (as emphasized in the 2017 Hypertension Clinical Practice Guidelines,4 new performance measures to assess quality of care in this regard have been included. 